Signase developed novel, small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. It was spun out of the M. D. Anderson Cancer Center. The company’s assets were acquired by Systems Medicine Inc. in 2005.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.